First-line treatment characteristics
| Characteristic . | Value . | Valid data (n) . |
|---|---|---|
| Total population, n (%) | 214 (100) | |
| Induction type, n (%) | 213 | |
| VD/VCD/PAD | 64 (30) | |
| VTD/VRD | 78 (36.6) | |
| VAD/DCEP | 55 (25.8) | |
| Other (thalidomide + dexamethasone) | 3 (1.4) | |
| No treatment (except radiotherapy) | 13 (6.1) | |
| ASCT, n (%) | 184 (93) | 198 |
| Single | 142 (77) | |
| Double | 42 (23) | |
| Consolidation OR maintenance therapy, n (%) | 108 (58.7) | 184 |
| Consolidation AND maintenance therapy, n (%) | 29 (15.8) | 184 |
| PI OR IMID first line, at any time, n (%) | 159 (79.9) | 199 |
| PI + IMID first line, at any time, n (%) | 104 (52.3) | 199 |
| Allo-HSCT, n (%) | 46 (24.9) | 185 |
| First line | 13 (28.9) | 45 |
| Second line | 22 (48.9) | 45 |
| Beyond second line | 10 (22.2) | 45 |
| Response to first-line therapy,* n (%) | 191 | |
| CR | 73 (38.2) | |
| VGPR | 64 (33.5) | |
| PR | 46 (24.1) | |
| Stable disease | 4 (2.1) | |
| Progressive disease | 4 (2.1) |
| Characteristic . | Value . | Valid data (n) . |
|---|---|---|
| Total population, n (%) | 214 (100) | |
| Induction type, n (%) | 213 | |
| VD/VCD/PAD | 64 (30) | |
| VTD/VRD | 78 (36.6) | |
| VAD/DCEP | 55 (25.8) | |
| Other (thalidomide + dexamethasone) | 3 (1.4) | |
| No treatment (except radiotherapy) | 13 (6.1) | |
| ASCT, n (%) | 184 (93) | 198 |
| Single | 142 (77) | |
| Double | 42 (23) | |
| Consolidation OR maintenance therapy, n (%) | 108 (58.7) | 184 |
| Consolidation AND maintenance therapy, n (%) | 29 (15.8) | 184 |
| PI OR IMID first line, at any time, n (%) | 159 (79.9) | 199 |
| PI + IMID first line, at any time, n (%) | 104 (52.3) | 199 |
| Allo-HSCT, n (%) | 46 (24.9) | 185 |
| First line | 13 (28.9) | 45 |
| Second line | 22 (48.9) | 45 |
| Beyond second line | 10 (22.2) | 45 |
| Response to first-line therapy,* n (%) | 191 | |
| CR | 73 (38.2) | |
| VGPR | 64 (33.5) | |
| PR | 46 (24.1) | |
| Stable disease | 4 (2.1) | |
| Progressive disease | 4 (2.1) |
Number of patients is expressed in absolute value (n) whereas percentage (%) is calculated among valid data, after exclusion of ND and NA values. DCEP, cyclophosphamide + etoposide + doxorubicin + prednisone; PAD, bortezomib + Adriamycin + dexamethasone; VAD, vincristine + Adriamycin + dexamethasone; VCD, bortezomib + cyclophosphamide + dexamethasone; VD, bortezomib + dexamethasone; VRD, bortezomib + lenalidomide + dexamethasone; VTD, bortezomib + thalidomide + dexamethasone.
Response to first-line therapy was assessed by using International Myeloma Working Group criteria.